Viewing StudyNCT04629703



Ignite Creation Date: 2024-05-06 @ 3:24 PM
Last Modification Date: 2024-10-26 @ 1:49 PM
Study NCT ID: NCT04629703
Status: COMPLETED
Last Update Posted: 2023-08-18
First Post: 2020-11-13

Brief Title: Double-Blind Randomized Placebo-Controlled Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
Sponsor: Rigel Pharmaceuticals
Organization: Rigel Pharmaceuticals

Conditions & Keywords Data

Conditions:
Name
Pneumonia Viral
Covid19
SARS Severe Acute Respiratory Syndrome
SARS Pneumonia
SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere
Pneumonia
Keywords:
Name View
Pneumonia Viral View
COVID19 View
SARS-Associated Coronavirus Pneumonia View